Abstract
Since over 20 years platelet transfusions are established therapy allowing prolonged survival of patients with hematologic and hemato-oncologic diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Grumet FC, Yankee RA. Long-term platelet support of patients with aplastic anaemia. Ann Intern Med 1970;73:1–7.
Tejada F, Bias WB, Santos GW, Zieve PD. Immunologic response of patients with acute leukemia to platelet transfusions. Blood 1973;42:405–12.
Schiffer LA, Lichenfeld JL, Wiernik PH, et al. antibody response in patients with acute nonlymphocyte leukemia. Cancer 1976;37:2177–82.
Howard JE, Perkins HA. The natural history of alloimmunization to platelets. Transfusion 1978;18:496–503.
Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Alloimmunization following platelet transfusion: the absence of a dose response relationship. Blood 1981;57:395–8.
Holohan TV, Terasaki PI, Deisseroth AB. Suppression of transfusion-related alloimmunization in intensively treated cancer patients. Blood 1981;58:122–8.
Eernisse JG, Brand A. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Exp Hematol 1981;9:77–83.
Ford JM, Brown LM, Cullen MH, et al. Combined granulocyte and platelet transfusions — development of alloimmunization as reflected by decreasing cell recovery values. Transfusion 1982;22:498–504.
Pegels JG, Bruynes ECE, Korthals Altes HR, et al. Immune unresponsiveness to platelets. Vox Sang 1982;42:211–6.
McFarland JG, Slichter SJ, Appelbaum F. Alloimmune versus consumptive platelet refractoriness in AML. Blood 1982;60(suppl 1):18a.
Murphy MF, Metcalf P, Thomas H, et al. Use of leukocyte-poor blood products and HLA matched donors to prevent alloimmunization by platelet transfusions. Brit J Haematol 1988;62:529–34.
Klingeman HG, Self S, Banaji M, et al. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: Multivariate analysis of data from 264 cases. Brit J Haematol 1987;66:115–21.
Brand A, Claas FMJ, Voogt PJ, et al. Alloimmunization after leukocyte depleted multiple random donor platelet transfusions. Vox Sang 1988;54:160–6.
Sniecinski I, O’Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-immunization using filtered blood products. Blood 1988;5:1402–7.
Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964–9.
Novotny VMJ, van Doom R, Rozier Y, D’Amaro J, Harvey MS, Brand A. Transfusion results of filtered and subsequently stored random platelet suspensions prepared from buffy coats. Vox Sang 1992;63:23–30.
Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J. Factors influencing 20-hour increments after platelet transfusion. Transfusion 1991;31:392–6.
Heal JM, Cowles J, Masel D, Rowe JM, Blumberg N. Antibodies to plasmaproteins: An association with platelet transfusion refractoriness. Brit J Haematol 1992;80:83–90.
Godeau B, Fromont P, Seror T, Duedari N, Bierling P. Platelet alloimmunization after multiple transfusions: A prospective study of 50 patients. Brit J Haematol 1992; 81:395–400.
Murphy MI, Waters AJ. Immunological aspects of platelet transfusions. Brit J Haematol 1985;60:409–14.
McGrath K, Wolf M, Bishop J, et al. Transient platelet and HLA antibody formation in multitransfused patients with malignancy. Brit J Haematol 1988;68:345–60.
Van Marwijk-Kooy M, van Prooyen HC, Moes M, Bosma-Stants I, Akkerman JW. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA-alloimmunization: A prospective randomized trial. Blood 1991;77: 201–5.
Fisher M, Chapman JR, Ting A, Morris PJ. Alloimmunization to HLA antigens following transfusion with leukocyte-poor and purified platelet suspensions. Vox Sang 1985;49:331–5.
Claas FMJ, Smeenk RJ, Schmidt R, van Steenbrugge GJ, Eernisse JG. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981; 9:84–9.
Bergstresser PR, Sullivan S, Streilein JW, Tigelaar RE. Origin and function of Thy-1 dendritic epidermal cells in mice. J Invest Dermatol 1985;85:90–26.
Sintnicolaas K, van Prooyen HC, van Marwijk-Kooy M, van Dijk BA, van Putten WLJ, Brand A. Leukocyte depletion of random single donor platelet transfusion for the prevention of secondary alloimmunization in patients with previous pregnancies. Brit J Haematol 1991;79:674(abstract).
Lagaay EM, Henneman PH, Ruigrok M, et al. Effect of one HLA-DR antigen matched and completely HLA-DR mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 1989;321:701–5.
Van Twuyer E, Hooyaert RJD, ten Berge IJM. Pretransplantation blood transfusion revisited. N Engl J Med 1991;325:1210–3.
Hendriks GFJ, Schreuder GMTh, Claas FHJ, et al. HLA-DRw6 and renal allograft rejection. Brit Med J 1983;286:85–87.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Brand, A. (1993). Alloimmunization and Platelet Transfusion Refractoriness. In: Sibinga, C.T.S., Das, P.C., The, T.H. (eds) Immunology and Blood Transfusion. Developments in Hematology and Immunology, vol 28. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3094-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3094-7_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6352-1
Online ISBN: 978-1-4615-3094-7
eBook Packages: Springer Book Archive